Modality
Bispecific Ab
MOA
IL-17i
Target
LAG-3
Pathway
Tau
Crohn'sHNSCC
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
Feb 2021
→ Feb 2030
Phase 1Current
NCT05137245
1,584 pts·HNSCC
2021-02→2030-02·Not yet recruiting
1,584 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-155mo agoEMA Filing· Crohn's
2030-02-153.9y awayInterim· HNSCC
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Not yet…
Catalysts
EMA Filing
2025-10-15 · 5mo ago
Crohn's
Interim
2030-02-15 · 3.9y away
HNSCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05137245 | Phase 1 | HNSCC | Not yet recr... | 1584 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |